The early components in the classical pathway of complement activation bind to antibody-antigen aggregates or antibody-coated cells, resulting in a multimolecular complex formed from the fourth, second and third components C423. This complex has proteolytic activity and will activate the fifth component, which forms a further complex with the later components C36789 causing the lysis of cells (Muller-Eberhard, 1975; Fothergill & Anderson, 1978; Porter, 1978) . The formation of these biologically active complexes appears to be an essential feature of the complement system, but little is known of the molecular basis of these reactions.
The formation of the C423 complex depends on the binding of the first component, Cl, which contains three subcomponents Clq, Clr and Cls, to aggregated or cell-bound antibody. Component Cl binds to the second constant domain of IgG antibody via Clq. Two molecules each of Clr and Cls form a tetrameric complex in the presence of Ca2+, which binds to Clq through Clr. The bound Cl complex develops proteolytic activity which is responsible for the activation of C4 and C2. Components C4 and C2 form an active complex C42 (C3 convertase) (Muller- Polley & Muller-Eberhard, 1968) which activates C3, which in turn associates to give the C423 complex with the capacity to activate C5 (Goldlust etal., 1974; Cooper & Muller-Eberhard, 1970) .
In this work we have compared the ability of antibody bound to erythrocytes and of antibody aggregated by a soluble protein antigen first to bind and activate CI and then in turn to bind C4 and develop C3 convertase activity. We have found that antibody on erythrocytes binds similar amounts of Cl as equal amounts of antibody in aggregates, but results in 10-1 3-fold more binding of C4 to sensitized cells than to aggregates.
Much of the C4 bound, however, is ineffective in the complement sequence, as judged by the development of C3 convertase activity in the presence of excess C2; about 95 % is ineffective when bound to sensitized cells and 50% when bound to antibody aggregates. Indirect evidence suggests that the effective C4 molecules are those bound to the Fab portions either very close to or on the same IgG molecules which are binding Cl on their Fc sections.
Materials and Methods Materials and buffers
Veronal-buffered saline containing 0.142M-NaCl, 5mM-sodium barbital, 0.15mM-CaCl2 and 1 mMMgCl2, pH7.4, was prepared fresh daily from 5-fold concentrated stock. Low-ionic-strength buffer was prepared by diluting veronal-buffered saline with an equal volume of 5 % (w/v) glucose. Phosphatebuffered saline contained 0.15M-NaCl and 0.01M-potassium phosphate, pH7.4. Buffered balanced salt solution was prepared as described by Shortman (1968) . Veronal-buffered saline/glucose was used in all experiments unless mentioned otherwise. Sephadex G-200, Sephadex G-50, DEAESephadex A-50, CM-Sephadex C-50, Sepharose 6B and CL-Sepharose 6B were obtained from Pharmacia Fine Chemicals, Uppsala, Sweden.
Complement components
Functionally pure human CT was obtained as a euglobulin precipitate of human serum. One part of serum was mixed for 2h at 4°C with 4 parts of 5mM-CaCl2, pH7.4. The resultant precipitate was washed once with 0.04M-sodium acetate/5 mM-CaCl2, pH 5.5, and 'then dissolved in 0.2M-NaCl/5 mMsodium acetate/ 5 mM-CaCl2 /0.01 % NaN3, pH 5.5. Finally, the lipid was removed by centrifugation at 75000g for 30min. Fractions were stored at -700C for months. Before adsorption on sensitized erythrocytes or immune aggregates, the CT was activated fully by dilution with vol. of 5% (w/v) glucose/ 0.01M-Tris/HCl, and the pH adjusted to 7.4 with 1 M-NaOH. After incubation at 30°C for 45min the CT was clarified by centrifugation at 10OOg for 30min.
Human Clq and CIs were prepared as described by Reid (1974) and Gigli et al. (1976) . Both Clq and Cls preparations showed at least 95 % homogeneity on polyacrylamide-gel electrophoresis in sodium dodecyl sulphate.
Guinea-pig CT was prepared in functionally pure form as an euglobulin precipitate by the method of Nelson et al. (1966) .
Human C4 was purified as described by Gigli et al. (1977) . Briefly, the C4 was purified from a pseudoglobulin fraction ofhuman serum by chromatography on DEAE-Sephadex A-50 and Sepharose 6B. After the DEAE-Sephadex chromatography step, C4 was functionally free from Cl, C2 and C3 and was used for titration experiments. Chemically homogeneous C4 obtained after Sepharose 6B chromatography was used for immunization and standards in the specific radioimmunoassay for C4.
Human C2 was prepared by a modified procedure of Kerr & Porter (1978) . After chromatography of pseudoglobulin on CM-Sephadex C-50 and precipitation by 75 %-satd. (NH4)2SO4, the precipitate resulting from 500ml of serum was dissolved in 0.03 M-sodium phosphate/0.01 % NaN3, pH7.8, and dialysed overnight at 4°C against the same buffer. The sample was applied to a column (3.5 cm x 35 cm) of DEAE-Sephadex A-50 equilibrated at 40C in 0.03 M-sodium phosphate/0.01 % NaN3, pH7.8. After a washing with 500ml of the column buffer, C2 was eluted with 0.10M-NaCl/0.03M-sodium phosphate/ 0.01 % NaN3, pH 7.8. C2 prepared in this manner was functionally free of Cl, C4 and C3 and was stable for months at -70°C.
Guinea-pig C2 was prepared functionally pure as described by Borsos et al. (1961) .
Human C3 was obtained by the modified procedure of Nilsson & Muller-Eberhard (1965) and Tack & Prahl (1976) . The precipitate formed at pH 5.5 obtained from the C4 purification scheme of Gigli et al. (1977) The haemolytic activities of whole-serum complement CH50, Cl, C2, C4, C3 and C5 were determined by the methods'of Becker (1956) , Borsos & Rapp (1967) , Glovsky & Fudenberg (1970) , Ruddy & Austen (1967) and Tack & Prahl (1976) 
Antibody preparations
Rabbit anti-(sheep erythrocyte) serum was prepared as described by Mayer (1961 (Jensenius & Williams, 1974 ).
Antisera to human Clq, Cls, C4 and ovalbuimin were prepared by immunization of rabbits with purified antigens. A first injection of 200pg of antigen into the left thigh muscle was followed 1 week later by a second injection into the right thigh muscle. Finally, 100,g of antigen was injected intravenously 7 days later and bleeding from the ear veins was started at weekly intervals thereafter. Against whole human serum in Ouchterlony double-diffusion assays (Ouchterlony, 1953) all antisera showed only one band and no cross-reaction with related proteins such as Clq, CIr, Cls, C4, C3, ovalbumin and rabbit IgG. Antibody (Fab')2 fractions of the purified antibodies were also obtained as follows. Pure antigens were coupled to CL-Sepharose 6B after activation with CNBr (Cuatrecasas & Anfinsen, 1971) . The antisera were passed through affinity columns containing their respective antigen. Specific antibodies were then eluted with 1 M-propionic acid and adjusted to pH7.8 with an equal volume of 1 M-Tris/HCl. After dialysis against phosphatebuffered saline, (Fab')2 fractions from antisera against components Clq, Cls and C4 were obtained by pepsin digestion (Fanger et al., 1970) . All (Fab')2 antibody preparations showed inhibition only by their respective antigen in radioimmunoassays with human Clq, Clr, Cls, C4, C3, rabbit IgG and ovalbumin.
Antigen-antibody aggregates
Ovalbumin-anti -ovalbumin aggregates were formed with rabbit IgG anti-ovalbumin. The IgG fraction was obtained after three precipitations of antiserum with 45 %-satd. (NH4)2SO4, chromatography on DEAE-Sephadex A-50 in 0.03 M-potassium phosphate, pH 8.0, and chromatography on Sephadex G-200 in phosphate-buffered saline. An (Fab')2 fraction was obtained by pepsin digestion (Fanger et al., 1970) . Ovalbumin-anti-ovalbumin aggregates were formed with optimum amounts of ovalbumin at 4°C overnight in phosphate-buffered saline. The precipitates were washed three times in phosphatebuffered saline and finally resuspended in 0.15M-Vol. 175 NaCl /0.01 % NaN3 /1 mM-di-isopropyl phosphorofluoridate. Immune aggregates were also prepared containing a mixture of IgG and (Fab')2 anti-ovalbumin, and referred to as 'hybrid' aggregates. Hybrid aggregates containing 80% (Fab')2 and 20% IgG (molar ratios) were prepared with optimal ovalbumin concentrations at 4°C overnight with constant stirring. Less than 5 % ofthe original protein remained in solution, indicating that both types of antibodies were utilized in the aggregate formation.
Iodination of immunoglobulins
Radioiodination of antibody preparations with 1251 was done with chloramine-T (Byrt & Ada, 1969 sample in 75,ul were incubated for 15-20h at room temperature with 1.5 x 105c.p.m. of 1251-labelled (Fab')2 antibody raised against the antigen to be detected. The samples were then centrifuged at 3000g for 30min to pellet any labelled antibody bound to aggregates, and 100,ul of the supernatant was transferred to 501 containing 1 x 107 antigen-coated target cells. After 1 h at room temperature, the target cells were washed twice and finally counted for radioactivity in an LKB 1270 Rackgamma gamma counter. Low-ionic-strength buffer with 0.1 % bovine serum albumin was used throughout.
The radioactivity of the target cells was plotted against the dilutions of the test sample. The 50% midpoint of the resultant sigmoidal binding curve was compared with a standard antigen curve to obtain the concentration of antigen in the sample. Samples run in duplicates were always within 5 % of each other.
Target cells
Rat or sheep erythrocytes were washed three times in balanced buffered salt solutions and resuspended to 2.5 x 108 cells/ml. Then 100 ml of cells and an equal volume of 0.25% glutaraldehyde were mixed for 5min at room temperature; 20ml of 10% (w/v) bovine serum albumin was then added, followed by immediate centrifugation at 1000g for 10min and washing in balanced buffered salt solutions/0.1 % bovine serum albumin. The fixed cells were finally suspended in saline to 2.5 x 108 cells/ml. Human Clq, Cls or C4 were linked to the fixed rat cells by the CrCl3 method of Parish & Hayward (1974) Increasing amounts of cell-bound or aggregated antibody were added to human serum, and both the total complement and the C4 remaining in the supernatant after incubation at 37°C for I h were assayed. Consumption of both whole complement and C4 followed a sigmoidal curve when similar amounts of either cell-bound or aggregated antibody were added (Fig. 1) . The somewhat higher effectiveness of the cell-bound antibody may be due to its greater availability when spread on the cell surface compared with insoluble aggregates, but the small difference suggests that the cell surface as such has no direct role. These and subsequent haemolytic assays were accurate to ±15 %. CT. If sensitized cells or aggregates were incubated with C4 for 30min at 30°C and the bound C4 was estimated after a centrifuging and washing, both complexes showed increased binding with increasing C4 concentration (Fig. 3) and a maximum per 1000 molecules of antibody close to 1200 for aggregates and about 16000 for cell-bound antibody. This is in agreement with previous reports that activated C4 binds to the erythrocyte membrane (MiillerEberhard & Lepow, 1965 Cooper & Muller-Eberhard (1968) . This was in contrast with the binding of CT, which in antibody excess is more than 90% complete. The maximum uptake of C4 varied somewhat, depending on the preparation of C4 used, although the cells always bound 10-13-fold more C4 than did aggregates. This variability could not be traced to differences in purity, specific activity or age of the C4 preparations.
Effectiveness of C4 bound to sensitized cells and aggregates in the haemolytic system There was a 10-13-fold difference between the relative amount of C4 bound between sensitized cells and aggregates carrying the same amount of antibody, but only a 1.5-2-fold difference in their ability to activate the whole complement system. This suggested (Fig. 6) , showing that the binding of both total and effective C4 molecules is proportional to the number of CT molecules present. This supports the view that rapidity of binding after activation is an essential feature in utilization of C4.
Attempt to locate the bound C4 molecule on antibodyantigen aggregates It is known that Cl binds to the Fc portion of aggregated antibody (Ishizaka et al., 1962) , but where C4 binds is uncertain. Attempts to allocate the C4-binding site to the Fab or the Fc portion of the antibody were unsuccessful by hydrolysis of the complex with papain or other proteinases. Either little splitting occurred or C4 was destroyed. Therefore an indirect measure was made by using antibodyantigen aggregates made up of either whole antibody or whole antibody and (Fab')2 fragments. The antibody and (Fab')2 fragments were stirred during addition of antigen to ensure as intimate a mixture as possible during precipitation. Both whole antibody or mixed aggregates were then incubated with CT, washed, and finally C4 binding was measured after incubation with increasing C4 concentrations. Fig. 7 shows that, with constant bound CT, the C4 bound is the same in both whole antibody and in the mixed antibody-(Fab')2 aggregates in the molar proportions 1:4. When (Fab')2 aggregates were treated similarly, a low but significant binding of CT and of C4 occurred, possibly owing to a small contamination (< 5%) of the (Fab')2 with whole antibody C is molecules bound per 1000 molecules of antibody Fig. 6 .7I
Assembly of early components of complement on cell bound antibody Fig. 8 . Suggested assembly of CT, C4 and C2 molecules on an antibody-coated cell surface Previous evidence (Porter, 1977) has shown that Clq binds to the CH2 domain of aggregated IgG and that Clr2-Ca2+-CTs2 complex binds to the collagenous tails of Clq. Most C4 and C2 molecules activated by CTs will become inactivated (C4i and C2i) in solution, but some C4 will bind either to the antibody molecules (probably the Fab portion) or to the cell surface. Some C2 will bind to C0 on the Fab portion of the same IgG molecules as carry CT or adjacent molecules. C4 molecules on the cell surface or on more distant lgG molecules will not bind C2, as it will be inactivated in solution before reaching them. The site of binding of C4 and of the C42 complex is likely to be the Fab part of the antibody molecule. Chan & Cebra (1968) showed that, if antibody used to form an antigen-antibody precipitate was first 'pre-split' by resin-coupled papain and then the precipitate dissolved with reducing agent, the soluble Fab aggregates, but not Fc, gave a reaction with anti-C4 antiserum in double-diffusion gels. Subsequent elucidation of the disulphide-bond :arrangement of antibodies makes the interpretation of their work uncertain. Our attempts to achieve mild conditions for the digestion of antibody aggregates without destruction of bound complement components were unsuccessful. However, the ability of aggregates, made with either whole antibody or a mixture of whole antibody and (Fab')2 fragments, to bind similar amounts of C4 when carrying constant amounts of CT suggests that C4 is in fact bound to the Fab part of the antibody molecule. This is in agreement with the conclusion of Chan & Cebra (1968) , and, as other experiments showed that C4 binding increases with the increasing amounts of antibody aggregates present, when the Cl content was constant, the binding of C4 cannot be to Cl but is most likely to be to the Fab part of the molecule. A more direct demonstration of this point would, however, be desirable.
The diagram in Fig. 8 summarizes the suggested assembly ofthe earlycomplement components. Earlier evidence summarized by Porter (1977) shows that the 'heads' of the Clq molecule bind to antibody via the CH2 domain of Fc and that the Clr2-Ca2 -Cls2 tetrameric complex binds to the collagenous tails of Clq, leading to activation of CTs. CTs activates C4, a small fraction ofwhich binds either to antibody or to the cell surface. Muller-Eberhard et al. (1967) have shown that, if C4 is bound to erythrocytes without antibody, subsequent addition of C2 and CTs in solution followed by EDTA-treated serum to supply the late complement components will cause lysis. This indicates that cell-bound C4 can form complex C42 and continue the complement sequence if C2 is activated in solution, some of the active molecules being close to the bound C4.
The inefficiency of cell-bound C4 relative to antibody-bound C4 (Fig. 4) is therefore likely to be due to inactivation of C2 in diffusing the greater distance from the place of activation by Cls bound to Clq on the Fc portion of the antibody molecules to C4 molecules on the cell surface compared with C4 on the same or closely adjacent antibody molecules.
If this interpretation of the results is correct, the cell-bound C4 molecules will be capable of forming C3 convertase, but in practice the C2 molecules will be inactivated before reaching them. Alternatively, if C42 diffuses as a complex C2 will be inactivated before C4 binds to the cell.
